US Patent Issued to Memorial Sloan-Kettering Cancer Center on Nov. 18 for "Seneca valley virus (SVV) cellular receptor targeted oncotherapy" (New York Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,472,218, issued on Nov. 18, was assigned to Memorial Sloan-Kettering Cancer Center (New York).

"Seneca valley virus (SVV) cellular receptor targeted oncotherapy" was invented by Linde Miles (New York), John Poirier (New York) and Charles Rudin (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a ca...